Skip to main content
Top
Published in: Diabetologia 8/2005

01-08-2005 | Article

Retinal neovascularisation without ischaemia in the spontaneously diabetic Torii rat

Authors: H. Yamada, E. Yamada, A. Higuchi, M. Matsumura

Published in: Diabetologia | Issue 8/2005

Login to get access

Abstract

Aims/hypothesis

The spontaneously diabetic Torii (SDT) rat has recently been established as a model of type 2 human diabetes mellitus. Male SDT rats develop severe diabetic ocular complications. This study investigated the nature of the ocular complications in this model and addressed the question of whether the SDT rat is a good model of human proliferative diabetic retinopathy.

Methods

Male SDT rats aged 50 weeks were studied for a period of 8 months. Under deep anaesthesia, one eye of each animal was enucleated following perfusion with fluorescein dextran and a retinal flat mount was prepared to study vascular structure. The other eye was enucleated and investigated histologically by haematoxylin–eosin and azan staining and by immunohistochemistry using antibodies against vascular endothelium (Griffonia simplicifolia isolectin B4 antibody) and vascular endothelial growth factor (VEGF).

Results

From the vascular structure study, 17 of 32 rats (53%) showed proliferative retinopathy without vascular non-perfusion. The histological study revealed traction retinal folds in rats with proliferative retinopathy. Azan staining showed some proliferative matrix in rats with normal retinal structure and those with proliferative retinopathy compared with normoglycaemic controls. Staining with Griffonia simplicifolia isolectin B4 antibody showed no specific vascular changes in any of the rats, while VEGF staining revealed higher immunoreactivity in the retina of rats with normal retinal structure and those with proliferative retinopathy, but only low immunoreactivity in the control animals.

Conclusions/interpretation

There appear to be differences between the SDT rat model of diabetic retinopathy and human proliferative diabetic retinopathy, as the SDT rat develops retinal neovascularisation without retinal ischaemia. This very unique display of ocular neovascularisation may be caused by increased expression of VEGF.
Literature
1.
go back to reference Kern T, Kowlulu R, Engerman R (1994) Questions raised by studies of experimental diabetic retinopathy. Elsevier Science, Japan Kern T, Kowlulu R, Engerman R (1994) Questions raised by studies of experimental diabetic retinopathy. Elsevier Science, Japan
2.
go back to reference Kador PF, Takahashi Y, Wyman M, Ferris F III (1995) Diabetes-like proliferative retinal changes in galactose-fed dogs. Arch Ophthalmol 113:352–354PubMed Kador PF, Takahashi Y, Wyman M, Ferris F III (1995) Diabetes-like proliferative retinal changes in galactose-fed dogs. Arch Ophthalmol 113:352–354PubMed
3.
go back to reference Buechi E, Kurosawa A, Tso M (1996) Retinopathy in diabetic hypertensive monkeys: a pathologic study. Graefes Arch Clin Exp Ophthalmol 234:388–398PubMed Buechi E, Kurosawa A, Tso M (1996) Retinopathy in diabetic hypertensive monkeys: a pathologic study. Graefes Arch Clin Exp Ophthalmol 234:388–398PubMed
4.
go back to reference Sima AA, Chakrabarti S, Garcia-Salinas R, Basu PK (1985) The BB-rat – an authentic model of human diabetic retinopathy. Curr Eye Res 4:1087–1092 Sima AA, Chakrabarti S, Garcia-Salinas R, Basu PK (1985) The BB-rat – an authentic model of human diabetic retinopathy. Curr Eye Res 4:1087–1092
5.
go back to reference Mansford KR, Opie L (1968) Comparison of metabolic abnormalities in diabetes mellitus induced by streptozotocin or by alloxan. Lancet 1:670–671CrossRefPubMed Mansford KR, Opie L (1968) Comparison of metabolic abnormalities in diabetes mellitus induced by streptozotocin or by alloxan. Lancet 1:670–671CrossRefPubMed
6.
go back to reference Hanafusa T, Maiyagawa J, Nakajima H et al (1994) The NOD mouse. Diabetes Res Clin Prac 24[Suppl]:S307–S311CrossRef Hanafusa T, Maiyagawa J, Nakajima H et al (1994) The NOD mouse. Diabetes Res Clin Prac 24[Suppl]:S307–S311CrossRef
7.
go back to reference Peterson R, Shaw M, Neel M-A, Eichberg J (1990) Zucker diabetic fatty rat as model for non-insulin-dependent diabetes melllitus. ILAR News 32:16–19 Peterson R, Shaw M, Neel M-A, Eichberg J (1990) Zucker diabetic fatty rat as model for non-insulin-dependent diabetes melllitus. ILAR News 32:16–19
8.
go back to reference Berdanier CD (1991) The BHE rat: an animal model for the study of non-insulin-dependent diabetes mellitus. FASEB J 5:2139–2144PubMed Berdanier CD (1991) The BHE rat: an animal model for the study of non-insulin-dependent diabetes mellitus. FASEB J 5:2139–2144PubMed
9.
go back to reference Kuwano K, Hirashima T, Mori S, Saitoh Y, Kurosumi T, Natori T (1992) Spontaneous long-term hyperglycemic rat with diabetic complications: Otsuka–Long–Evans–Tokushima Fatty (OLETF) strain. Diabetes 41:1248–1422 Kuwano K, Hirashima T, Mori S, Saitoh Y, Kurosumi T, Natori T (1992) Spontaneous long-term hyperglycemic rat with diabetic complications: Otsuka–Long–Evans–Tokushima Fatty (OLETF) strain. Diabetes 41:1248–1422
10.
go back to reference Engerman R, Finkelstein D, Aguirre G et al (1982) Ocular complications. Diabetes 31[Suppl 1]:82–88PubMed Engerman R, Finkelstein D, Aguirre G et al (1982) Ocular complications. Diabetes 31[Suppl 1]:82–88PubMed
11.
go back to reference Shinohara M, Masuyama T, Shoda T et al (2000) A new spontaneously diabetic non-obese Torii rat strain with severe ocular complications. Int J Exp Diabetes Res 1:89–100PubMed Shinohara M, Masuyama T, Shoda T et al (2000) A new spontaneously diabetic non-obese Torii rat strain with severe ocular complications. Int J Exp Diabetes Res 1:89–100PubMed
12.
go back to reference Smith L, Woesolowski E, McLellan A et al (1994) Oxygen-induced retinopathy in the mouse. Invest Ophthalmol Vis Sci 35:101–111PubMed Smith L, Woesolowski E, McLellan A et al (1994) Oxygen-induced retinopathy in the mouse. Invest Ophthalmol Vis Sci 35:101–111PubMed
13.
go back to reference Masuyama T, Komeda K, Hara A et al (2003) Chronological characterization of diabetes development in male spontaneously diabetic Torii rats. Biochem Biophys Res Commun 314:870–877CrossRef Masuyama T, Komeda K, Hara A et al (2003) Chronological characterization of diabetes development in male spontaneously diabetic Torii rats. Biochem Biophys Res Commun 314:870–877CrossRef
14.
go back to reference Aiello L, Avery R, Arig P et al (1994) Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med 331:1480–1487CrossRefPubMed Aiello L, Avery R, Arig P et al (1994) Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med 331:1480–1487CrossRefPubMed
15.
go back to reference Adamis A, Miller J, Bernal M-T et al (1994) Increased vascular endothelial growth factor levels in the vitreous of eyes with proliferative diabetic retinopathy. Am J Ophthalmol 118:445–450PubMed Adamis A, Miller J, Bernal M-T et al (1994) Increased vascular endothelial growth factor levels in the vitreous of eyes with proliferative diabetic retinopathy. Am J Ophthalmol 118:445–450PubMed
16.
go back to reference Gerhardinger C, Brown LF, Roy S, Mizutani M, Zucker CL, Lorenzi M (1998) Expression of vascular endothelial growth factor in the human retina and in nonproliferative diabetic retinopathy. Am J Pathol 152:1453–1462PubMed Gerhardinger C, Brown LF, Roy S, Mizutani M, Zucker CL, Lorenzi M (1998) Expression of vascular endothelial growth factor in the human retina and in nonproliferative diabetic retinopathy. Am J Pathol 152:1453–1462PubMed
17.
go back to reference Pe’er J, Folberg R, Itin A, Gnessin H, Hemo I, Keshet E (1996) Upregulated expression of vascular endothelial growth factor in proliferative diabetic retinopathy. Br J Ophthalmol 80:241–245PubMed Pe’er J, Folberg R, Itin A, Gnessin H, Hemo I, Keshet E (1996) Upregulated expression of vascular endothelial growth factor in proliferative diabetic retinopathy. Br J Ophthalmol 80:241–245PubMed
18.
go back to reference Amin RH, Frank RN, Kennedy A, Eliott D, Puklin JE, Abrams GW (1997) Vascular endothelial growth factor is present in glial cells of the retina and optic nerve of human subjects with nonproliferative diabetic retinopathy. Invest Ophthalmol Vis Sci 38:36–47PubMed Amin RH, Frank RN, Kennedy A, Eliott D, Puklin JE, Abrams GW (1997) Vascular endothelial growth factor is present in glial cells of the retina and optic nerve of human subjects with nonproliferative diabetic retinopathy. Invest Ophthalmol Vis Sci 38:36–47PubMed
19.
go back to reference Murata T, Nakagawa K, Khalil A, Ishibashi T, Inomata H, Sueishi K (1996) The relation between expression of vascular endothelial growth factor and breakdown of the blood-retinal barrier in diabetic rat retinas. Lab Invest 74:819–825PubMed Murata T, Nakagawa K, Khalil A, Ishibashi T, Inomata H, Sueishi K (1996) The relation between expression of vascular endothelial growth factor and breakdown of the blood-retinal barrier in diabetic rat retinas. Lab Invest 74:819–825PubMed
20.
go back to reference Sone H, Kawakami Y, Okuda Y et al (1997) Ocular vascular endothelial growth factor levels in diabetic rats are elevated before observable retinal proliferative changes. Diabetologia 40:726–730CrossRefPubMed Sone H, Kawakami Y, Okuda Y et al (1997) Ocular vascular endothelial growth factor levels in diabetic rats are elevated before observable retinal proliferative changes. Diabetologia 40:726–730CrossRefPubMed
21.
go back to reference Hammes HP, Lin J, Bretzel RG, Brownlee M, Breier G (1998) Upregulation of the vascular endothelial growth factor/vascular endothelial growth factor receptor system in experimental background diabetic retinopathy of rat. Diabetes 47:401–406PubMed Hammes HP, Lin J, Bretzel RG, Brownlee M, Breier G (1998) Upregulation of the vascular endothelial growth factor/vascular endothelial growth factor receptor system in experimental background diabetic retinopathy of rat. Diabetes 47:401–406PubMed
22.
go back to reference Boulton M, Foreman D, Williams G, McLeod D (1998) VEGF localisation in diabetic retinopathy. Br J Ophthalmol 82:561–568PubMed Boulton M, Foreman D, Williams G, McLeod D (1998) VEGF localisation in diabetic retinopathy. Br J Ophthalmol 82:561–568PubMed
23.
go back to reference Pierce E, Avery R, Foley E, Aiello L, Smith L (1995) Vascular endothelial growth factor/vascular permeability factor expression in a mouse model of retinal neovascularization. Proc Natl Acad Sci U S A 92:905–909PubMed Pierce E, Avery R, Foley E, Aiello L, Smith L (1995) Vascular endothelial growth factor/vascular permeability factor expression in a mouse model of retinal neovascularization. Proc Natl Acad Sci U S A 92:905–909PubMed
24.
go back to reference Rand LI, Prud’homme GJ, Ederer F, Canner PL, Group tDRS (1985) Factors influencing the development of visual loss in advanced diabetic retinopathy. Invest Ophthalmol Vis Sci 26:983–991PubMed Rand LI, Prud’homme GJ, Ederer F, Canner PL, Group tDRS (1985) Factors influencing the development of visual loss in advanced diabetic retinopathy. Invest Ophthalmol Vis Sci 26:983–991PubMed
25.
go back to reference Kishi S, Shimizu K (1993) Clinical manifestations of posterior precortical vitreous pocket in proliferative diabetic retinopathy. Ophthalmology 100:225–229PubMed Kishi S, Shimizu K (1993) Clinical manifestations of posterior precortical vitreous pocket in proliferative diabetic retinopathy. Ophthalmology 100:225–229PubMed
Metadata
Title
Retinal neovascularisation without ischaemia in the spontaneously diabetic Torii rat
Authors
H. Yamada
E. Yamada
A. Higuchi
M. Matsumura
Publication date
01-08-2005
Publisher
Springer-Verlag
Published in
Diabetologia / Issue 8/2005
Print ISSN: 0012-186X
Electronic ISSN: 1432-0428
DOI
https://doi.org/10.1007/s00125-005-1809-0

Other articles of this Issue 8/2005

Diabetologia 8/2005 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.